advertisement
14 Costing studies; pharmacoeconomics (14)
Showing records 1 to 14
Display all abstracts in classification 14 Costing studies; pharmacoeconomics
Search within classification 14 Costing studies; pharmacoeconomics47842 Identification of diseases for EQ-5d bolt-on item development: An empirical approach
Solem CT; Gu NY; Pickard AS
Value in Health 2011; 14: A428
48296 Community optometrist referral of those aged 65 and over for raised IOP post-NICE: AOP guidance versus joint college guidance--an epidemiological model using BEAP
Vernon SA; Hillman JG; Macnab HK; Bacon P; van der Hoek J; Vernon OK; Bhargarva A
British Journal of Ophthalmology 2011; 95: 1534-1546
48031 Gene patents related to common diseases of the eye
Sahebjada S; Cantsileris S; Baird PN
Recent Patents on DNA and Gene Sequences 2011; 5: 185-193
47832 Economic outcomes of glaucoma treatment with prostaglandin eye drops preserved with polyquad(registered trademark) instead of benzalkonium chloride in Germany
Gerlier L; Lamotte M; Lorenz K; Berdeaux G; Verboven Y; Pfeiffer N
Value in Health 2011; 14: A503
47841 Cost-effectiveness of the ex-press glaucoma filtration device in France
de Jong L; Lafuma A; Clement O; Aguade AS; Berdeaux G
Value in Health 2011; 14: A250-A251
47831 Cost of blindness in Austria
Brennig C; Schollbauer V; Walter E
Value in Health 2011; 14: A504-A505
47820 Cost-offset analysis: Bimatoprost versus other prostaglandin analogues in open-angle glaucoma
Berenson KL; Kymes S; Hollander DA; Fiscella R; Burk C; Patel VD
American Journal of Managed Care 2011; 17: e365-e374
47546 Eye care utilization in Canada: Disparity in the publicly funded health care system
Jin Y-P; Trope GE
Canadian Journal of Ophthalmology 2011; 46: 133-138
47611 Incidence and US Costs of Corticosteroid-Associated Adverse Events: A Systematic Literature Review
Sarnes E; Crofford L; Watson M; Dennis G; Kan H; Bass D
Clinical Therapeutics 2011; 33: 1413-1432
47839 Cost-effectiveness of the ex-press glaucoma filtration device in the Netherlands
de Jong L; Lafuma A; Aguade AS; Clement O; Berdeaux G
Value in Health 2011; 14: A250
47836 Glaucoma management cost as a function of disease stage and treatment changes
Gerlier L; Shlaen R; Lorenz K; Lamotte M; Verboven Y; Pfeiffer N
Value in Health 2011; 14: A505
48360 An assessment of the health and economic burdens of glaucoma
Varma R; Lee PP; Goldberg I; Kotak S
American Journal of Ophthalmology 2011; 152: 515-522
47810 Long-term outcomes of prostaglandin analog versus timolol maleate in ocular hypertensive or primary open-angle glaucoma patients in Europe
Hollo G; Thelen U; Teus MA; Quaranta L; Ferkova S; Babic N; Misiuk-Hojlo M; Mikropoulos DG; Kaluzny BJ; Kozobolis V
Journal of Ocular Pharmacology and Therapeutics 2011; 27: 493-498
47902 Health economical aspects of telemedical glaucoma monitoring
Swierk T; Jurgens C; Grossjohann R; Flessa S; Tost F
Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft 2011; 108: 342-350